北芯生命（688712）：心血管精准介入国产龙头

Investment Rating - The report gives the company an "Accumulate" rating for the first time, with expected earnings per share of 0.23 yuan and 0.34 yuan for 2025 and 2026, respectively, corresponding to valuations of 174 times and 119 times [5]. Core Insights - The company is a leading domestic player in cardiovascular precision intervention, focusing on innovative medical devices for cardiovascular disease diagnosis and treatment [6][13]. - The precision PCI market in China is expected to grow rapidly, with the market size projected to increase from 2.04 billion yuan in 2022 to 9.42 billion yuan by 2030, reflecting a compound annual growth rate (CAGR) of approximately 21.1% [6][43]. - The company has established a comprehensive product pipeline and solution for precision intervention, leveraging its four core technology platforms to maintain a competitive edge in the market [6][26]. Summary by Sections Company Overview - The company specializes in the research, development, production, and sales of innovative medical devices for cardiovascular diseases, with core products including the IVUS diagnostic system and FFR measurement system, both of which are the first domestically approved products in their respective categories [13][22]. - The company has achieved significant recognition and awards, including being designated as a "National Specialized and New 'Little Giant' Enterprise" and a provincial manufacturing champion [13][14]. Business Performance - The company has experienced rapid revenue growth, with revenues increasing from 0.02 billion yuan in 2020 to 3.12 billion yuan in 2024, representing a CAGR of 270.81% [26][27]. - The core product, the IVUS diagnostic system, has become a major revenue source, accounting for over 60% of the company's main business income in recent years [29]. Market Trends - The PCI market in China is expected to see a significant increase in surgical volume, projected to grow from 1.906 million procedures in 2024 to 4.298 million by 2030, with a CAGR of approximately 14.5% [40][41]. - The penetration rate of precision PCI technologies like FFR and IVUS is expected to rise, driven by increasing awareness and demand for precise diagnosis and treatment in cardiovascular care [51][47].